Varian has announced the release date for its third quarter fiscal year 2020 earnings. The results will be disclosed after market close on August 5, 2020. Following the announcement, a teleconference will take place at 1:30 p.m. Pacific Time. Investors can dial in to access the call or join via the live webcast available on the company’s website. This session allows stakeholders to gain insights into Varian's financial performance and business strategies.
Summary not available.
Results from the SABR-COMET study, published June 2, 2020, indicate that stereotactic ablative radiotherapy (SABR) significantly improves overall survival in patients with oligometastatic cancers. Patients receiving SABR showed a 22-month increase in 5-year median overall survival, equating to a 24.6% absolute survival benefit over standard care. The findings support SABR as a viable treatment option and suggest a shift in treatment paradigms for low burden metastatic disease. Ongoing trials aim to further validate these benefits.